Compare Stocks: ORKA, GMAB, EXEL, and ASND

Comparative Price Performance Over Time

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$229.23 +2.9%	$246.62	$186.05 ▼ $282.15	$13.89B	0.38	969,992 shs	815,738 shs
EXEL Exelixis	$59.86 +1.4%	$56.26	$33.76 ▼ $61.14	$14.62B	0.47	2.22 million shs	2.67 million shs
GMAB Genmab A/S	$37.07 +2.8%	$33.61	$23.62 ▼ $40.17	$22.50B	0.81	3.89 million shs	2.33 million shs
ORKA Oruka Therapeutics	$82.11 +6.3%	$94.58	$24.31 ▼ $115.51	$5.12B	-0.37	1.06 million shs	1.21 million shs

7 Stocks to Buy Before the Robotics Revolution

Robotics and automation are rapidly becoming essential infrastructure across healthcare, manufacturing, logistics, and many other industries. "Physical AI" is coming. Learn which seven companies are most positioned to benefit as intelligent robots enter the workforce.

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+2.94%	+0.60%	-12.11%	-15.24%	+9.09%
EXEL Exelixis	+1.42%	+2.52%	+2.62%	+5.95%	+54.92%
GMAB Genmab A/S	+2.83%	+6.68%	+12.20%	+27.83%	+13.23%
ORKA Oruka Therapeutics	+6.25%	-2.85%	-10.26%	-5.39%	+263.16%

Compare Price & Volume

Company	Current Price	50-Day Moving Average	52-Week Range	Market Cap	Beta	Avg. Volume	Today's Volume
ASND Ascendis Pharma A/S	$229.23 +2.9%	$246.62	$186.05 ▼ $282.15	$13.89B	0.38	969,992 shs	815,738 shs
EXEL Exelixis	$59.86 +1.4%	$56.26	$33.76 ▼ $61.14	$14.62B	0.47	2.22 million shs	2.67 million shs
GMAB Genmab A/S	$37.07 +2.8%	$33.61	$23.62 ▼ $40.17	$22.50B	0.81	3.89 million shs	2.33 million shs
ORKA Oruka Therapeutics	$82.11 +6.3%	$94.58	$24.31 ▼ $115.51	$5.12B	-0.37	1.06 million shs	1.21 million shs

7 Stocks to Buy Before the Robotics Revolution

Get This Free Report

Compare Price Performance

Company	1-Day Performance	7-Day Performance	30-Day Performance	90-Day Performance	1-Year Performance
ASND Ascendis Pharma A/S	+2.94%	+0.60%	-12.11%	-15.24%	+9.09%
EXEL Exelixis	+1.42%	+2.52%	+2.62%	+5.95%	+54.92%
GMAB Genmab A/S	+2.83%	+6.68%	+12.20%	+27.83%	+13.23%
ORKA Oruka Therapeutics	+6.25%	-2.85%	-10.26%	-5.39%	+263.16%

Compare Analyst Forecasts

Company	Consensus Rating Score	Consensus Rating	Consensus Price Target	% Upside from Current Price
ASND Ascendis Pharma A/S	3.00	Buy	$313.21	36.64% Upside
EXEL Exelixis	2.35	Hold	$50.79	-15.16% Downside
GMAB Genmab A/S	2.85	Moderate Buy	$42.50	14.65% Upside
ORKA Oruka Therapeutics	2.82	Moderate Buy	$128.91	57.00% Upside

Current Analyst Ratings Breakdown

Latest ORKA, GMAB, EXEL, and ASND Analyst Ratings

Date	Company	Brokerage	Action	Rating	Price Target
10/9/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$51.00
10/8/2026	EXEL Exelixis	Weiss Ratings Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Upgrade	Buy (A-) ➝ Buy (A)
10/8/2026	EXEL Exelixis	Royal Bank Of Canada Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Lower Price Target	Sector Perform	$46.00 ➝ $45.00
10/7/2026	ORKA Oruka Therapeutics	Piper Sandler Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight
10/7/2026	EXEL Exelixis	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Hold	$52.00 ➝ $54.00
10/7/2026	GMAB Genmab A/S	Truist Financial Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $45.00
10/7/2026	GMAB Genmab A/S	HC Wainwright Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$40.00 ➝ $50.00
10/5/2026	GMAB Genmab A/S	Guggenheim Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Boost Price Target	Buy	$45.00 ➝ $54.00
9/25/2026	ASND Ascendis Pharma A/S	Cantor Fitzgerald Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Overweight	$300.00
9/24/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Set Price Target		$120.00
9/24/2026	ORKA Oruka Therapeutics	Wedbush Subscribe to MarketBeat All Access for the firm's recommendation accuracy rating	Reiterated Rating	Outperform	$165.00

(Data available from 10/10/2023 forward. View 10+ years of historical ratings with our analyst ratings screener.)

Compare Sales & Book Value

Company	Annual Revenue	Price/Sales	Cashflow	Price/Cash	Book Value	Price/Book
ASND Ascendis Pharma A/S	$814.57M	17.55	N/A	N/A	($2.97) per share	-77.18
EXEL Exelixis	$2.32B	6.39	$3.07 per share	19.50	$8.06 per share	7.43
GMAB Genmab A/S	$3.72B	6.22	$1.65 per share	22.40	$9.10 per share	4.07
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	$9.69 per share	N/A

Compare Profitability & Earnings

Company	Net Income	EPS	Trailing P/E Ratio	Forward P/E Ratio	P/E Growth	Net Margins	Return on Equity (ROE)	Return on Assets (ROA)	Next Earnings Date
ASND Ascendis Pharma A/S	-$258M	$12.89	17.78	25.67	N/A	70.99%	32.54%	7.71%	11/11/2026 (Estimated)
EXEL Exelixis	$782.57M	$3.18	18.82	16.09	1.76	35.33%	42.17%	31.76%	11/3/2026 (Estimated)
GMAB Genmab A/S	$963M	$1.27	29.19	23.02	1.67	19.08%	14.89%	7.73%	11/5/2026 (Estimated)
ORKA Oruka Therapeutics	-$105.43M	-$2.03	N/A	N/A	N/A	N/A	-21.65%	-20.88%	11/11/2026 (Estimated)

Latest ORKA, GMAB, EXEL, and ASND Earnings

Date	Quarter	Company	Consensus Estimate	Reported EPS	Beat/Miss	Gap EPS	Revenue Estimate	Actual Revenue
11/5/2026	Q3 2026	GMAB Genmab A/S	$0.37	N/A	N/A	N/A	$1.20 billion	N/A
11/3/2026	Q3 2026	EXEL Exelixis	$0.8780	N/A	N/A	N/A	$646.95 million	N/A
8/14/2026	Q2 2026	ASND Ascendis Pharma A/S	$1.71	$1.0270	-$0.6830	$3.23	$376.75 million	$387.22 million
8/10/2026	Q2 2026	ORKA Oruka Therapeutics	-$0.5125	-$0.55	-$0.0375	-$0.55	N/A	N/A
8/6/2026	Q2 2026	GMAB Genmab A/S	$0.37	$0.54	+$0.17	$0.4910	$1.12 billion	$1.16 billion
8/5/2026	Q2 2026	EXEL Exelixis	$0.8530	$0.91	+$0.0570	$0.8438	$636.40 million	$628.69 million

Compare Dividends

Company	Annual Payout	Dividend Yield	5-Year Annualized Dividend Growth	Payout Ratio	Years of Consecutive Growth
ASND Ascendis Pharma A/S	N/A	N/A	N/A	N/A	N/A
EXEL Exelixis	N/A	N/A	N/A	N/A	N/A
GMAB Genmab A/S	N/A	N/A	N/A	N/A	N/A
ORKA Oruka Therapeutics	N/A	N/A	N/A	N/A	N/A

Compare Debt

Company	Debt-to-Equity Ratio	Current Ratio	Quick Ratio
ASND Ascendis Pharma A/S	0.27	2.99	2.32
EXEL Exelixis	N/A	3.46	3.38
GMAB Genmab A/S	0.81	2.46	2.44
ORKA Oruka Therapeutics	N/A	38.51	38.51

Compare Ownership

Institutional Ownership

Company	Institutional Ownership
ASND Ascendis Pharma A/S	N/A
EXEL Exelixis	85.27%
GMAB Genmab A/S	7.07%
ORKA Oruka Therapeutics	56.44%

Insider Ownership

Company	Insider Ownership
ASND Ascendis Pharma A/S	40.00%
EXEL Exelixis	2.60%
GMAB Genmab A/S	1.54%
ORKA Oruka Therapeutics	23.49%

Compare Miscellaneous Stats

Company	Employees	Shares Outstanding	Free Float	Optionable
ASND Ascendis Pharma A/S	1,189	62.38 million	37.43 million	Optionable
EXEL Exelixis	1,077	247.78 million	241.34 million	Optionable
GMAB Genmab A/S	3,029	624.06 million	614.45 million	Optionable
ORKA Oruka Therapeutics	68	66.21 million	50.66 million	N/A

ORKA, GMAB, EXEL, and ASND Headlines

Recent News About These Companies

ORKA-002 Phase 1 Milestone: What Oruka’s First-in-Human Trial Means for Investors

October 9 at 12:31 PM | tipranks.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Consensus Target Price of $128.91

October 8 at 2:28 AM | americanbankingnews.com

Oruka Therapeutics, Inc. (NASDAQ:ORKA) Stock Has Average Target Price of $128.91 According to Analysts

October 8 at 2:28 AM | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) Shares Down 4.3% - Time to Sell?

October 6, 2026 | marketbeat.com

Oruka Therapeutics (NASDAQ:ORKA) CEO Lawrence Otto Klein Sells 25,000 Shares of Stock

October 3, 2026 | americanbankingnews.com

Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

October 3, 2026 | insidertrades.com

Insider Selling: Oruka Therapeutics (NASDAQ:ORKA) CEO Sells $2,090,500.00 in Stock

October 2, 2026 | marketbeat.com

Analysts Offer Insights on Healthcare Companies: Oruka Therapeutics (ORKA) and Co-Diagnostics (CODX)

September 25, 2026 | theglobeandmail.com

Analysts Are Bullish on These Healthcare Stocks: Immunovant (IMVT), Oruka Therapeutics (ORKA)

September 24, 2026 | theglobeandmail.com

Oruka Therapeutics' Psoriasis Treatment Maintains 'Competitive Profile' After Positive Clinical Data, UBS Says

September 24, 2026 | finance.yahoo.com

ORKA-002 Trial Progress: What Oruka’s New HS Study Means for Investors

September 24, 2026 | tipranks.com

ORKA Stock Down 5% Despite Positive Week 28 Psoriasis Efficacy Data

September 24, 2026 | zacks.com

Wedbush Reiterates "Outperform" Rating for Oruka Therapeutics (NASDAQ:ORKA)

September 24, 2026 | marketbeat.com

HC Wainwright Reaffirms "Buy" Rating for Oruka Therapeutics (NASDAQ:ORKA)

September 24, 2026 | marketbeat.com

What Oruka Therapeutics (ORKA)'s Phase 2a Psoriasis Data Means For Shareholders

September 23, 2026 | finance.yahoo.com

Oruka Therapeutics Announces Positive Week 28 Results From EVERLAST-A Phase 2a Trial Of ORKA-001

September 23, 2026 | marketscreener.comM

Update: Oruka Shares Fall Despite Deepening Week 28 Responses for ORKA-001

September 23, 2026 | finance.yahoo.com

Oruka Therapeutics (NASDAQ:ORKA) Shares Down 7.4% - Here's Why

September 23, 2026 | marketbeat.com

Oruka's ORKA-001 shows deepening psoriasis response at week 28

September 23, 2026 | streetinsider.com

Oruka Therapeutics Shares Fall 5% After Week 28 ORKA-001 Trial Data

September 23, 2026 | finance.yahoo.com

Oruka Therapeutics Reports Deepening Responses for ORKA-001 Through Week 28

September 23, 2026 | marketscreener.comM

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, GMAB, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

$229.23 +6.54 (+2.94%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$229.14 -0.09 (-0.04%)

As of 10/9/2026 07:30 PM Eastern

Ascendis Pharma A/S, a biopharmaceutical company, focuses on developing therapies for unmet medical needs. It offers SKYTROFA for treating patients with growth hormone deficiency (GHD). The company is also developing a pipeline of three independent endocrinology rare disease product candidates in clinical development, as well as focuses on advancing oncology therapeutic candidates. The company was incorporated in 2006 and is headquartered in Hellerup, Denmark.

Exelixis NASDAQ:EXEL

$59.86 +0.84 (+1.42%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$60.06 +0.20 (+0.33%)

As of 10/9/2026 07:57 PM Eastern

Exelixis, Inc., an oncology company, focuses on the discovery, development, and commercialization of new medicines for difficult-to-treat cancers in the United States. The company offers CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ capsules for the treatment of progressive and metastatic medullary thyroid cancer. Its CABOMETYX and COMETRIQ are derived from cabozantinib, an inhibitor of multiple tyrosine kinases, including MET, AXL, RET, and VEGF receptors. The company also offers COTELLIC, an inhibitor of MEK as a combination regimen to treat specific forms of advanced melanoma; and MINNEBRO, an oral non-steroidal selective blocker of the mineralocorticoid receptor for the treatment of hypertension in Japan. It develops zanzalintinib, a novel, potent, next-generation oral tyrosine kinase inhibitor (TKI) that targets VEGF receptors, MET and the TAM kinases (TYRO3, AXL and MER); and XB002, a next-generation tissue factor (TF)-targeting ADC, administered via intravenous infusion and composed of a human monoclonal antibody (mAb) against TF that is conjugated to an auristatin-based microtubulin inhibitor (MTI) payload. It has research collaborations and license agreements with Ipsen Pharma SAS; Takeda Pharmaceutical Company Ltd.; F. Hoffmann-La Roche Ltd.; Redwood Bioscience, Inc.; R.P. Scherer Technologies, LLC; Catalent Pharma Solutions, Inc.; NBE Therapeutics AG; Aurigene Discovery Technologies Limited; Iconic Therapeutics, Inc.; Invenra, Inc.; StemSynergy Therapeutics, Inc.; Genentech, Inc.; Bristol-Myers Squibb Company; and Daiichi Sankyo Company, Limited, as well as clinical development agreement with Sairopa B.V. for ADU-1805. The company was formerly known as Exelixis Pharmaceuticals, Inc. and changed its name to Exelixis, Inc. in February 2000. Exelixis, Inc. was incorporated in 1994 and is headquartered in Alameda, California.

Genmab A/S NASDAQ:GMAB

$37.07 +1.02 (+2.83%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$37.06 -0.01 (-0.03%)

As of 10/9/2026 07:37 PM Eastern

Genmab A/S develops antibody therapeutics for the treatment of cancer and other diseases primarily in Denmark. The company markets DARZALEX, a human monoclonal antibody for the treatment of patients with multiple myeloma (MM); teprotumumab for the treatment of thyroid eye disease; and Amivantamab for advanced or metastatic gastric or esophageal cancer and NSCLC. Its products include daratumumab to treat MM, non-MM blood cancers, and AL amyloidosis; GEN1047; tisotumab vedotin for treating cervical, ovarian, and solid cancers; DuoBody-PD-L1x4-1BB, and DuoBody-CD40x4-1BB for treating solid tumors; Epcoritamab for relapsed/refractory diffuse large B-cell lymphoma and chronic lymphocytic leukemia; and HexaBody-CD38 and GEN3017 for treating hematological malignancies. In addition, the company develops Inclacumab, which is in Phase 3 trial for vaso-occlusive crises; Camidanlumab tesirine to treat hodgkin lymphoma and solid tumors; JNJ-64007957 and JNJ-64407564 to treat MM; PRV-015 for treating celiac disease; Mim8 for treating haemophilia A; and Lu AF82422 for treating multiple system atrophy disease. It operates various active pre-clinical programs. The company has a commercial license and collaboration agreement with Seagen Inc. to co-develop tisotumab vedotin. It also has a collaboration agreement with argenx to discover, develop, and commercialize novel therapeutic antibodies with applications in immunology and oncology; and AbbVie for the development of epcoritamab, as well as collaborations with BioNTech, Janssen, and Novo Nordisk A/S. Genmab A/S was founded in 1999 and is headquartered in Copenhagen, Denmark.

Oruka Therapeutics NASDAQ:ORKA

$82.11 +4.83 (+6.25%)

Closing price 10/9/2026 04:00 PM Eastern

Extended Trading

$82.18 +0.08 (+0.09%)

As of 10/9/2026 07:56 PM Eastern

Oruka Therapeutics, Inc. is a biotechnology company, which focuses on developing novel monoclonal antibody therapeutics for PsO and other I&I indications. Its pipeline includes ORKA-001 and ORKA-002. The company is headquartered in Menlo Park, CA.

More Stock Comparisions from MarketBeat

More Stock Ideas from MarketBeat

Stock Lists

Low Priced Stocks

Stocks By Exchange

Latest Stock Ideas

Unlock superior investment research and tools.

Get MarketBeat All Access

In-depth profiles and analysis for 20,000 public companies.
Real-time analyst ratings, insider transactions, earnings data, and more.
Our daily ratings and market update email newsletter.

Sign In
Create Account

Your Email Address:

Your Password:

Forgot your password?

Your Email Address:

Choose a Password:

By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORKA, GMAB, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORKA, GMAB, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORKA, GMAB, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, GMAB, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Genmab A/S NASDAQ:GMAB

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools

About MarketBeat

MarketBeat Products

Popular Tools

Financial Calendars

Terms & Info

Compare Stocks

Comparative Price Performance Over Time

Compare Price & Volume

Compare Price Performance

Compare Price & Volume

Compare Price Performance

Compare Analyst Forecasts

Current Analyst Ratings Breakdown

Latest ORKA, GMAB, EXEL, and ASND Analyst Ratings

Compare Sales & Book Value

Compare Profitability & Earnings

Latest ORKA, GMAB, EXEL, and ASND Earnings

Compare Dividends

Compare Debt

Compare Ownership

Institutional Ownership

Insider Ownership

Compare Miscellaneous Stats

ORKA, GMAB, EXEL, and ASND Headlines

Recent News About These Companies

New MarketBeat Followers Over Time

Media Sentiment Over Time

ORKA, GMAB, EXEL, and ASND Company Descriptions

Ascendis Pharma A/S NASDAQ:ASND

Exelixis NASDAQ:EXEL

Genmab A/S NASDAQ:GMAB

Oruka Therapeutics NASDAQ:ORKA

More Stock Comparisions from MarketBeat

Stock Comparison Ideas (A-K)

Stock Comparison Ideas (L-Z)

More Stock Ideas from MarketBeat

MarketBeat All Access Features

Best-in-Class Portfolio Monitoring

Stock Ideas and Recommendations

Advanced Stock Screeners and Research Tools